Organ transplantation is underutilized despite donor availability, only a fraction of organs are used for transplants due to issues with organ quality, transportation logistics, and limited resources for many heart centers. The current standard of care to transport human organs (hearts, livers, kidneys) for transplantation is the Igloo cooler. Using the Igloo cooler only allows up to 4 hours to transport viable organs for transplant. Because of this Time Limitation, there is also a corresponding Geographic Limitation which limits the number of available organs that are transplanted in the U.S. Using current technology, 70%%20of otherwise available Hearts, 40%%20of otherwise available Kidneys, and 60%%20of otherwise available Lungs are lost and unable to be transplanted per year, in the U.S. This prevents 10,000s of lives from being saved or improved Vascular Perfusion Solutions (VP.S) is a medical technology company that has developed the VP.S ENCORE® which is designed to expand the time for transporting a viable organ for transplantation and keep transplantable organs healthier and of better quality for transplant. The VP.S ENCORE® is a single-use (Hypothermic Oxygenated Perfusion) system that contains a pump, oxygenator and filter that within a reusable transport case smaller than carry-on luggage. It uses off-the-shelf perfusate solution (vs. whole blood) and has already demonstrated in preclinical studies it can double cross-clamp time from a standard 4 hours to 8 hours with improved Left Ventricle (LV) contractility and superior cardiac function. The device is intended to increase organ utilization rate by preserving an additional 60%%20of donated hearts (8,000) that are currently discarded per year, and eventually becoming the Standard of Care. These advantages allow for Providers-Efficient and cost-effective solution to improve transplant center outcomes and increase organ utilization rate (currently 70%%20of available hearts are not used), Patients-shorter wait list (as availability of hearts will increase, especially to smaller heart centers, by doubling viability time), better clinical outcomes, fewer complications, and Payers-lower patient costs (reducing circulatory support, intra-aortic balloon pump, extracorporeal membrane oxygenation and/or ventricular assist devices and utilizing fewer days in the intensive care unit) Initial market opportunity: U.S. Cardiac Market $165M (5%%20CAGR) 35 major cardiac transplant centers, 57 organ procurement organizations --> Global Cardiac Market $363M and/or $1.7B U.S. transplantation market
